Mika Mizuno

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 929 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

Mika Mizuno, Fumitaka Kikkawa, Kiyosumi Shibata et al. · Journal of Surgical Oncology · 2006 · 102 citations

Medicine, Gynecology, Oncology +17

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata et al. · Institutional Repositories DataBase (IRDB) · 2021 · 82 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study

Mitsuya Ishikawa, Takahiro Kasamatsu, Hitoshi Tsuda et al. · Gynecologic Oncology · 2017 · 81 citations

Medicine, Gynecology, Oncology +17